PH25819A - Linear, cyclic analog of alpha-msh fragments with extraordinary potency - Google Patents

Linear, cyclic analog of alpha-msh fragments with extraordinary potency

Info

Publication number
PH25819A
PH25819A PH36969A PH36969A PH25819A PH 25819 A PH25819 A PH 25819A PH 36969 A PH36969 A PH 36969A PH 36969 A PH36969 A PH 36969A PH 25819 A PH25819 A PH 25819A
Authority
PH
Philippines
Prior art keywords
linear
alpha
cyclic analog
extraordinary potency
msh fragments
Prior art date
Application number
PH36969A
Other languages
English (en)
Inventor
Victor J Hruby
Fahad A Al-Obeidi
Mac E Hadley
Original Assignee
Victor J. Hruby
Fahad A. Al-Obeidi
Mac E. Hadley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victor J. Hruby, Fahad A. Al-Obeidi, Mac E. Hadley filed Critical Victor J. Hruby
Publication of PH25819A publication Critical patent/PH25819A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH36969A 1987-05-22 1988-05-23 Linear, cyclic analog of alpha-msh fragments with extraordinary potency PH25819A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5322987A 1987-05-22 1987-05-22
CA000578920A CA1340107C (en) 1987-05-22 1988-09-30 Linear and cyclic analoques of alpha-msh fragments with extraordinary potency

Publications (1)

Publication Number Publication Date
PH25819A true PH25819A (en) 1991-11-05

Family

ID=25672150

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36969A PH25819A (en) 1987-05-22 1988-05-23 Linear, cyclic analog of alpha-msh fragments with extraordinary potency

Country Status (11)

Country Link
EP (1) EP0292291B1 (de)
JP (1) JPH0826077B2 (de)
CN (1) CN1031242C (de)
AT (1) ATE109793T1 (de)
CA (1) CA1340107C (de)
DE (1) DE3851002T2 (de)
DK (1) DK172760B1 (de)
FI (1) FI882380A7 (de)
IE (1) IE64903B1 (de)
PH (1) PH25819A (de)
PT (1) PT87560B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683981A (en) * 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
EP0389950A1 (de) * 1989-03-23 1990-10-03 Lion Corporation Inhibitor des melanocytenstimulierenden Hormons und dieses enthaltendes, äusserlich anwendbares Präparat
US5071583A (en) * 1990-08-14 1991-12-10 Steve Martell Soap bar having a fifth finger gripping member
GB9102450D0 (en) * 1991-02-05 1991-03-20 Sandoz Ltd Improvements in or relating to organic compounds
US5364851A (en) * 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
FR2691465B1 (fr) * 1992-05-25 1995-08-11 Pf Medicament Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.
WO1994022460A1 (en) * 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
FR2710340B1 (fr) * 1993-09-22 1995-12-15 D Hinterland Lucien Dussourd Dérivés peptidiques de l'alpha-MSH et leur application .
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
TW200718944A (en) * 1999-06-29 2007-05-16 Univ New York Screening methods for compounds that affect melanogenesis
DE10228837B4 (de) * 2002-06-27 2016-01-07 Elfriede Rauch Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel
EP1670815A2 (de) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortinrezeptoragonisten
CA2582607C (en) * 2004-10-08 2016-07-12 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
CN100355776C (zh) * 2005-06-20 2007-12-19 中国人民解放军第二军医大学 一种新型α－黑素细胞刺激素类似物及其用途
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
DK2957292T3 (en) 2008-03-27 2018-01-22 Clinuvel Pharmaceuticals Ltd VITILIGOTERAPHY
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
US8338565B2 (en) 2008-08-20 2012-12-25 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
CN102816211B (zh) * 2012-09-10 2014-07-23 南京工业大学 一种制备美那诺坦的方法
EP2970388B1 (de) 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptidzusammensetzungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US448539A (en) 1891-03-17 Cornelius s morris
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin

Also Published As

Publication number Publication date
EP0292291A2 (de) 1988-11-23
CA1340107C (en) 1998-10-27
DK172760B1 (da) 1999-06-28
DK277788D0 (da) 1988-05-20
FI882380A0 (fi) 1988-05-20
IE64903B1 (en) 1995-09-20
IE881537L (en) 1988-11-22
EP0292291A3 (en) 1990-05-02
JPS6470499A (en) 1989-03-15
JPH0826077B2 (ja) 1996-03-13
PT87560B (pt) 1992-09-30
ATE109793T1 (de) 1994-08-15
FI882380A7 (fi) 1988-11-23
CN1031242C (zh) 1996-03-13
DK277788A (da) 1988-11-23
PT87560A (pt) 1989-05-31
EP0292291B1 (de) 1994-08-10
AU1650688A (en) 1988-11-24
AU618733B2 (en) 1992-01-09
DE3851002T2 (de) 1995-02-02
DE3851002D1 (de) 1994-09-15
CN1032795A (zh) 1989-05-10

Similar Documents

Publication Publication Date Title
PH25819A (en) Linear, cyclic analog of alpha-msh fragments with extraordinary potency
PL266680A1 (en) Method of obtaining il-6 and of its application
DE68929551D1 (de) Menschliche DNase
ZA85206B (en) Protein conjugates useful in the treatment of thrombotic disease
AU1362488A (en) Topical composition and method for stimulating hair growth with stable free radicals
IL85712A0 (en) Lyophilized lymphokine composition
GB2223225B (en) Neutrophil-activating factor: its production and use in treatment
GB8819826D0 (en) Glycosylated igf-1
DE3685484D1 (de)
ZA85973B (en) Hardenable composition and its use
AU6524386A (en) Method for administering vaccines and compositions therefor
NO863027L (no) Peptidpreparater med kontinuerlig avgivelse.
NZ223293A (en) Beta-alkyl melatonins and pharmaceutical compositions
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
MY104115A (en) Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
AU4672985A (en) Method of blending and molding mortars
NZ224348A (en) Tanning composition with al and ti
NZ215328A (en) 2-oxa or aza pregnanes and pharmaceutical compositions
ZA883550B (en) Linear cyclic analogs of alpha-msh fragments with extraordinary potency
NZ220242A (en) Regulating fertility in cattle by administering epostane
AU618733C (en) Linear and cyclic analogs of alpha-MSH fragments with extraordinary potency
IT8848116A0 (it) Composizione farmaceutica in particolare per il trattamento di alopecia e acne vulgaris e procedimento per prepararla
EP0195114A3 (en) Stabilized injection compositions and their preparations
JPS57175116A (en) Pharmacological composition for circular alopecia treatment and therapy thereby
GB2268062B (en) Use of gamma amino butyric acid autoreceptor antagonists for the treatment of pain